- Previous Close
0.8349 - Open
0.8200 - Bid 0.6860 x 200
- Ask 1.1200 x 200
- Day's Range
0.8000 - 1.0000 - 52 Week Range
0.8000 - 7.5000 - Volume
274,220 - Avg. Volume
573,318 - Market Cap (intraday)
17.572M - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-3.2500 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.50
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
bioviepharma.comRecent News: BIVI
View MorePerformance Overview: BIVI
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIVI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIVI
View MoreValuation Measures
Market Cap
15.50M
Enterprise Value
-8.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.65
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-63.41%
Return on Equity (ttm)
-154.54%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-25.53M
Diluted EPS (ttm)
-3.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
24.41M
Total Debt/Equity (mrq)
1.60%
Levered Free Cash Flow (ttm)
-14.18M